Partnering with microbiologists to diagnose and prevent diseaseTM

Anti-SARS-CoV-2 Rapid Test

Anti-SARS-COV-2 Banner

When you suspect the worst, you need rapid results.

Anti-SARS-CoV-2 Rapid Test is a rapid, one-step lateral flow assay intended for the presumptive qualitative detection of IgM and IgG antibodies to the SARS-CoV-2 virus in patients suspected of a COVID-19 infection.

IgM antibodies are generated initially by the body as a result of infection at about the time symptoms appear. They will dissipate within approximately one month. IgG antibodies are generated by the body about one week after symptoms appear and last for an extended amount of time.

By using a patient’s finger prick blood, serum, or plasma specimen, the Anti-SARS-CoV-2 Rapid Test offers a turnaround time of only 15 minutes.

Anti-SARS-CoV-2 kit

View the Online Catalog

This simple-to-use test requires no equipment or special expertise or training to implement.

•  Rapid Results – 15 minutes for a readout
•  No special equipment or facilities needed
•  Clear, easy-to-interpret results
•  Built-in controls
•  Room temperature storage
•  High sensitivity – 97.4%
•  High specificity – 96.2%

For Use with Blood:

Ant-SARS Method-Blood

For Use with Serum:

Ant-SARS Method-Serum

We’re here to partner with you in your effort to SAVE LIVES by delivering rapid results.

Now accepting orders for Anti-SARS-CoV-2 Rapid Test for COVID-19.

The new tentative ship date is now May 5th. However, we will certainly update you when more information becomes available.

This product is not available for purchase and resale by our distributor partners.

Anti-SARS-CoV-2 Rapid Test is an immunoassay intended for the presumptive qualitative detection of IgM and IgG antibodies to the SARS-CoV-2 virus in plasma from anticoagulated human blood (Heparin / EDTA / sodium citrate), serum, or capillary finger prick blood (no anticoagulants or additives) from individuals with signs and symptoms of infection who are suspected of COVID-19 infection. Testing is limited to certified laboratories able to perform highly complex tests in the laboratory.
The Anti-SARS-CoV-2 Rapid Test is intended for use by clinical laboratory personnel specifically instructed and trained in the techniques of in vitro diagnostic procedures.
This test should not be used as the sole basis for patient management decisions. Test results must be combined with clinical observations, patient history, and epidemiological information.
Follow-up testing with a molecular diagnostic test should be considered to confirm the infection status. This test is not intended for the screening of donated blood.
This test will be useful in identifying asymptomatic and mildly symptomatic carriers of the SARS-CoV-2 virus. It will also be helpful in identifying persons who were infected by the virus previously, but may not have been properly diagnosed.
Hardy Diagnostics has permission to sell this test under the FDA’s Emergency Use Authorization (EUA) program. Please note the following information:
  • This test has not been reviewed by FDA
  • Negative results do not rule out SARS-CoV-2 infection, particularly in those who have been in recent contact with the virus, due to the lag time between exposure and the patient’s antibody response. Follow-up testing with a molecular diagnostic test should be considered in order to rule out infection in these individuals.
  • Results from antibody testing should not be used as the sole basis to diagnose or exclude SARS-CoV-2 infection or to inform of infection status.
  • Positive results may be due to past or present infections with non-SARS-CoV-2 coronavirus strains, such as coronavirus HKU1, NL63, OC43 or 229E.
  • This test is for use by licensed laboratories and does not apply to at-home testing.
  • Not to be used for blood donor screening